B Raf (BRAF) Mutant (V600E) Rabbit Monoclonal Antibody [Clone ID: OTIR1F3]

CAT#: TA592461

BRAF mutant V600E Rabbit monoclonal antibody,clone OTIR1F3

Product Images

Figure A, Western blot analysis of overexpressed lysate from HEK293T cells transfected with empty plasmid (PS100001, lane NC) , BRAF V600E mutant plasmid (RC400155, lane V600E) and BRAF wild type plasmid (RC211013, lane WT) using anti-BRAF V600E antibody TA592461 (1:500). Figure B, Western blot analysis of the same samples as figure A with anti-DDK antibody (TA180144, 1:1000)

• 

  Immunohistology staining on BRAF mutant (V600E) overexpressed cytosection TS600155P5 with rabbit anti BRAF (V600E) clone OTIR1F3 C/N TA592461 at 1:2000 dilution 20m RT. Antibody staining was achieved with HIER Citrate pH6 , Polink1 with DAB chromogen detection kit (D11-18). Positive stain shown with the brown chromogen present. HEK293T cells were transfected with cDNA clone RC400155, 5 micron sections, 40x magnification

• 

  Immunohistology staining on BRAF overexpressed cytosection TS411013P5 with rabbit anti BRAF (V600E) clone OTIR1F3 C/N TA592461 at 1:2000 dilution 20m RT. Antibody staining was achieved with HIER Citrate pH6 , Polink1 with DAB chromogen detection kit (D11-18). Positive stain shown with the brown chromogen present. HEK293T cells were transfected with cDNA clone RC400155, 5 micron sections, 40x magnification

• 

  Immunohistology staining on Negative Control overexpressed cytosection TC400001 with rabbit anti BRAF (V600E) clone OTIR1F3 C/N TA592461 at 1:2000 dilution 20m RT. Antibody staining was achieved with HIER Citrate pH6 , Polink1 with DAB chromogen detection kit (D11-18). Positive stain shown with the brown chromogen present. 5 micron sections, 40x magnification

• 

Show all 5 images

Specifications

Product Data

• Clone Name: OTIR1F3
• Applications: IHC, WB
• Recommended Dilution: WB 1:500
• Reactivities: Human
• Host: Rabbit
• Isotype: IgG
• Clonality: Monoclonal
• Immunogen: Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human BRAF V600E (NP_004324). The exact sequence is proprietary.
• Formulation: PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.
• Concentration: 1 mg/ml
• Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
• Conjugation: Unconjugated
• Storage: Shipped at -20°C or with ice packs, Upon delivery store at -20°C. Dilute in PBS(pH7.3) if necessary. Stable for 12 months from date of receipt. Avoid repeated freeze-thaws.
• Gene Name: B-Raf proto-oncogene, serine/threonine kinase
• Database Link:
  NP_004324
  Entrez Gene 673 Human
  UniProt ID P15056
• Background: This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this gene has been identified on the X chromosome. [provided by RefSeq, Aug 2017]
• Synonyms: B-raf; B-RAF1; BRAF1; NS7; RAFB1

Reference Data

• Protein Families: Druggable Genome, Protein Kinase
• Protein Pathways: Acute myeloid leukemia, Bladder cancer, Chemokine signaling pathway, Chronic myeloid leukemia, Colorectal cancer, Endometrial cancer, ErbB signaling pathway, Focal adhesion, Glioma, Insulin signaling pathway, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanoma, mTOR signaling pathway, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Non-small cell lung cancer, Pancreatic cancer, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Regulation of actin cytoskeleton, Renal cell carcinoma, Thyroid cancer, Vascular smooth muscle contraction